2020
Morbidity and mortality after robot‐assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group
Mortezavi A, Crippa A, Edeling S, Pokupic S, Dell’Oglio P, Montorsi F, D'Hondt F, Mottrie A, Decaestecker K, Wijburg C, Collins J, Kelly J, Tan W, Sridhar A, John H, Canda A, Schwentner C, Rönmark E, Wiklund P, Hosseini A. Morbidity and mortality after robot‐assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group. BJU International 2020, 127: 585-595. PMID: 33058469, PMCID: PMC8246851, DOI: 10.1111/bju.15274.Peer-Reviewed Original ResearchConceptsPatients aged <Intracorporeal urinary diversionCancer-specific mortalityOther-cause mortalityPostoperative complicationsRadical cystectomyMortality rateUrinary diversionBladder cancerOutcomes of patients aged <Predictor of high-grade complicationsHigh-grade complication rateOther-cause mortality ratesRobot-assisted radical cystectomyMultivariate logistic regression analysisClavien-Dindo gradeLaparoscopic radical cystectomyHigh-grade complicationsPostoperative mortality rateMinimally invasive approachTreatment-related risksLogistic regression analysisOCM ratesPostoperative variablesComplication rateInequity in selective referral to high-volume hospitals for genitourinary malignancies
Berg S, Tully K, Sahraoui A, Tan W, Krimphove M, Marchese M, Lipsitz S, Noldus J, Trinh Q. Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology Seminars And Original Investigations 2020, 38: 582-589. PMID: 32217041, DOI: 10.1016/j.urolonc.2020.02.013.Peer-Reviewed Original ResearchConceptsHigh-volume hospitalsBladder cancerPredictors of treatmentCancer patientsRadical prostatectomyProstate cancerMuscle-invasive urothelial bladder cancerNegative predictors of treatmentBlack raceNational Cancer DatabaseNonmetastatic prostate cancerUrothelial bladder cancerProstate cancer patientsBladder cancer patientsMultivariate logistic regression modelAssociated with lower ratesKidney cancer patientsPrivate insurance statusAssociated with lower oddsAssociated with greater oddsLow-volume hospitalsRadical cystectomyReceipt of treatmentGenitourinary malignanciesPerioperative morbidityExploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
Tan W, Teo C, Chan D, Ang K, Heinrich M, Feber A, Sarpong R, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, Sridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette A, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor J, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies J, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Sinclair A, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris H, Culmsee C, Menzies A, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha A, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, Alty A, Zelhof B, Blades R. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach. BJU International 2020, 125: 669-678. PMID: 31975539, PMCID: PMC7318301, DOI: 10.1111/bju.15008.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancer diagnosisPatient experienceNon-muscle-invasive bladder cancerTransurethral resection of bladder tumorCancer diagnosisBrief IPQMixed-methods approachBrief Illness Perception QuestionnaireCause of bladder cancerRisk of bladder cancerMental health of patientsIllness Perception QuestionnairePersonal controlBladder cancerHealth of patientsSemi-structured interviewsPerception of disease controlLow personal controlMental healthProspective multicentre observational studyPsychological supportUrine biomarker studiesPerception QuestionnaireDiagnosis of non-muscle-invasive bladder cancerPoor perception
2019
Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer
Tan W, Krimphove M, Cole A, Marchese M, Berg S, Lipsitz S, Löppenberg B, Nabi J, Abdollah F, Choueiri T, Kibel A, Sooriakumaran P, Trinh Q. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer 2019, 17: e1060-e1068. PMID: 31303561, DOI: 10.1016/j.clgc.2019.06.008.Peer-Reviewed Original ResearchConceptsPositive surgical marginsFactors associated with positive surgical marginsPositive surgical margin statusPT2 prostate cancerRadical prostatectomyProstate cancerCancer-specific factorsSurgical approachMargin statusHigher hospital surgical volumeSurgical margin statusNational Cancer DatabaseHospital surgical volumeCancer-specific featuresPSM rateSurgical marginsCancer DatabaseImprove patient outcomesEvaluating patientsContribution of patientLogistic regression modelsSurgical volumeProstatectomyPatientsPatient-specificMixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance
Tan W, Teo C, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, ridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, inclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette M, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor A, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies A, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris M, Culmsee C, Menzies H, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha M, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, lty A, Zelhof B, Blades R. Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU International 2019, 124: 408-417. PMID: 30694612, PMCID: PMC6767410, DOI: 10.1111/bju.14690.Peer-Reviewed Original ResearchConceptsMinimally acceptable sensitivityAdverse eventsMixed-methods approachUrine biomarkersUrinary biomarkersProspective multicentre observational studyUrinary biomarker testsUrinary tract symptomsHome to hospitalAssociated with adverse eventsUrinary tract infectionHigh-risk patientsMulticentre observational studySensitivity of cystoscopyBladder cancer surveillanceDiagnosis of cancerSemi-structured interviewsPrevalence of haematuriaPatient experiencePatient perspectivePatients' viewsCancer surveillanceTract infectionsUrine biomarker studiesPatient demographicsDevelopment and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer
Tan W, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser C, Waisbrod S, Hermanns T, Sasieni P, Kelly J, Khetrapal P, Baker H, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Watson D, Knight H, Maher S, Rane A, Pathmanathan B, Harmathova A, Hellawell G, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann A, Cook J, Cornwell M, Mills R, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Gupwell K, Whiteley S, Brown A, McGrath J, Lunt N, Hill P, Sinclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Davies M, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, Speed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Rees A, Williams S, Dukes S, Goffe A, Dawson L, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Payne D, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K, Sarpong R, Brew‐Graves C, Williams N. Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. Journal Of Internal Medicine 2019, 285: 436-445. PMID: 30521125, PMCID: PMC6446724, DOI: 10.1111/joim.12868.Peer-Reviewed Original ResearchConceptsCancer risk scoreNational Institute for Health and Clinical Excellence guidelinesRisk scoreInvestigation of haematuriaPhysician decision-makingAge-specific thresholdsValidation cohortExcellence guidelinesUK hospitalsAmerican Urological Association guidelinesNational guidelinesImprove patientNo significant overfittingImprove patient selectionUpper tract cancerLack of consensusAssociation guidelinesSmoking historySwiss patientsCohortPatient ageDevelopment cohortPatient selectionGuidelinesHaematuria
2018
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measuresCan Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Feber A, Kelly J, Collaborators D. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? Journal Of Urology 2018, 200: 973-980. PMID: 29702097, PMCID: PMC6179963, DOI: 10.1016/j.juro.2018.04.065.Peer-Reviewed Original ResearchConceptsUpper tract urothelial cancerComputerized tomography urogramBladder ultrasoundIncidence of bladderUrinary tract cancerMicroscopic hematuriaUrothelial cancerBladder cancerIncidence of upper tract urothelial cancerIncidence of urinary tract cancerRenal calculiPredictive valueUpper tract imagingDetecting bladder cancerNegative predictive valueDetect renal cancerDiagnosed bladder cancerPositive predictive valueSuspected renal calculiHematuria casesMacroscopic hematuriaRenal cancerHematuriaInvestigated patientsCystoscopyWho Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients
Tan W, Feber A, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Kelly J, collaborators O. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. European Urology 2018, 74: 10-14. PMID: 29653885, DOI: 10.1016/j.eururo.2018.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overFemaleHematuriaHumansMaleMiddle AgedProspective StudiesRisk AssessmentUrologic NeoplasmsYoung AdultConceptsUrinary tract cancerIncidence of urinary tract cancerInvestigation of haematuriaRisk of urinary tract cancerClinically significant cancerDiagnosis of urinary tract cancerHigh-risk cancerProspective observational studyIncidence of cancerSignificant cancerAge thresholdBladder cancerSmoking historyVisible bloodOlder patientsHaematuriaMale genderConsensus recommendationsPatientsObservational studyCancerPatient preferencesCancer diagnosisLack of consensusAge
2017
Intracorporeal robot‐assisted radical cystectomy, together with an enhanced recovery programme, improves postoperative outcomes by aggregating marginal gains
Tan W, Tan M, Lamb B, Sridhar A, Mohammed A, Baker H, Nathan S, Briggs T, Tan M, Kelly J. Intracorporeal robot‐assisted radical cystectomy, together with an enhanced recovery programme, improves postoperative outcomes by aggregating marginal gains. BJU International 2017, 121: 632-639. PMID: 29124853, DOI: 10.1111/bju.14073.Peer-Reviewed Original ResearchConceptsLength of hospital stayOpen radical cystectomyRobot-assisted radical cystectomyPeri-operative outcomesRadical cystectomyERAS programmeERAS groupERAS pathwayReadmission ratesOpen radical cystectomy groupAmerican Society of Anesthesiologists scoreIntracorporeal robot-assisted radical cystectomyPeri-operative anaemiaLymph node yieldRadical cystectomy casesClavien-Dindo systemScore-matched cohort of patientsCohort of patientsLevel 1 evidenceImproving postoperative outcomesIntracorporeal urinary diversionBody mass indexScore-matched cohortGastrointestinal-related complicationsPrimary outcome measureUroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan W, Martínez-Fernández M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng K, Zeegers M, Bryan R, James N, Paramio J, Freeman A, Beck S, Kelly J. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics 2017, 9: 8. PMID: 28163793, PMCID: PMC5282868, DOI: 10.1186/s13148-016-0303-5.Peer-Reviewed Original ResearchConceptsDetection of bladder cancerEpigenetic alterationsSequencing assayNovel high-throughputBladder cancerBackgroundBladder cancerNext-generation sequencing assayUrinary biomarkersDNA methylationMuscle-invasive bladder cancerUrinary biomarker assaysSediment DNAAnalysis pipelineVoided urine samplesDetection of BCPrimary BCHigh-throughputCystoscopic examinationVoided urineDNAIndependent cohortAssayBiomarker panelDiagnosed BCCancer
2014
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer
Gurung P, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan W, Feber A, Crabb S, Short S, Freeman A, Powles T, Hoskin P, West C, Kelly J. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer. International Journal Of Cancer 2014, 136: 709-720. PMID: 24917520, DOI: 10.1002/ijc.29022.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerMuscle-invasive bladder cancer patientsTissue-microarrayBladder cancerAssociated with survivalPredictive of survivalMethylation-specific PCRColony forming assayLoss of expressionRadical cystectomyRadiotherapy trialsRadiosensitising effectPrognostic valueMechanism of gene silencingRadiotherapyResponse to ionising radiationClinical biomarkersPatientsProtein expressionCancerMeta-analysisDNA damage responseCystectomySurvivalBladder
2011
The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study)
Tan W, Ng C, Khoo E, Low W, Tan H. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). The Aging Male 2011, 14: 231-236. PMID: 22115177, DOI: 10.3109/13685538.2011.597463.Peer-Reviewed Original ResearchConceptsEtiology of erectile dysfunctionTestosterone deficiency syndromeFasting blood glucoseMetabolic syndromeMS componentsSelf-reported medical problemsDeficiency syndromeErectile dysfunctionInternational Index of Erectile FunctionSocio-demographic dataIndex of Erectile FunctionElevated fasting blood glucoseModerate-severe EDPredictors of EDElevated blood pressureHigher disease burdenMultivariate regression analysisAge of menIIEF-5Erectile functionDisease burdenPhysical examinationInternational IndexLipid profileUrban settings